Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-11
2006-07-11
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S175000, C514S176000, C514S182000, C514S826000, C540S097000, C540S109000, C540S112000, C540S115000, C552S548000, C552S551000, C552S553000, C552S554000
Reexamination Certificate
active
07074778
ABSTRACT:
This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and alleviating asthmatic responses to allergen. Exemplary 3-aminosteroid compounds used in the methods of the invention include compounds having the chemical formula (I), wherein X, R1, R2, R3, and R4groups are as defined herein. The invention also relates to certain novel compounds of formula (I). Moreover, the invention also provides methods for identifying an immunomodulatory 3-aminosteroid compound.
REFERENCES:
patent: 5250524 (1993-10-01), Kramer et al.
patent: 5637691 (1997-06-01), Frye et al.
patent: 5721226 (1998-02-01), Frye et al.
patent: 5733899 (1998-03-01), Frye et al.
patent: 5763430 (1998-06-01), Zasloff
patent: 5792635 (1998-08-01), Zasloff
patent: 5795885 (1998-08-01), Zasloff et al.
patent: 5840740 (1998-11-01), Zasloff et al.
patent: 5840936 (1998-11-01), Zasloff et al.
patent: 5847172 (1998-12-01), Zasloff et al.
patent: 5856535 (1999-01-01), Zasloff et al.
patent: 5874597 (1999-02-01), Jones
patent: 5908839 (1999-06-01), Levitt et al.
patent: 5994336 (1999-11-01), Zasloff et al.
patent: 2002/0156013 (2002-10-01), Renauld et al.
patent: WO 99/14242 (1999-03-01), None
Burrows et al. (1989) Association of asthma with serum IgE levels and skin-test reactivity to allergens, N. Engl. J. Med. 320:271-277.
Burrows et al. (1992) Relationships of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children, J. Allergy Clin. Immunol. 90:376-385.
Chang et al. (1994) Isolation and characterization of the human interleukin-9 receptor gene, Blood 83:3199-3205.
Clifford et al. (1987) Symptoms, atopy, and bronchial response to methacholine in parents with asthma and their children, Arch. Dis. Child. 62:66-73.
Doull et al. (1996) Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness, Am. J. Respir. Crit. Care Med. 153:1280-1284.
Dugas et al. (1993) Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes, Eur. J. Immunol. 23:1687-1692.
Eklund et al. (1993) Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases, J. Immunol. 151:4266-4273.
Gergen et al. (1991) The association of allergen skin test reactivity and respiratory disease among whites in the US population. Data from the Second National Health and Nutrition Examination Survey, 1976 to 1980, Arch. Intern. Med. 151:487-492.
Halonen et al. (1992) The predictive relationship between serum IgE levels at birth and subsequent incidences of lower respiratory illnesses and eczema in infants, Am. Rev. Respir. Dis. 146:866-870.
Houssiau et al. (1995) A cascade of cytokines is responsible for IL-9 expression in human T cells. Involvement of IL-2, IL-4, and IL-10, J. Immunol. 154:2624-2630.
Johannson et al. (1972) The clinical significance of IgE, Prog. Clin. Immunol. 1:157-181.
Jones et al. (1996) The synthesis and characterization of analogs of the antimicrobial compound squalamine: 6-beta-hydroxy-3-aminosterols synthesized from hyodeoxycholic acid, Steroids 61:565-571.
Kelleher et al. (1991) Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T cells, Blood 77:1436-1441.
Levitt et al. (1995) Linkage homology for bronchial hyperresponsiveness between DNA markers on human chromosome 5q31-q33 and mouse chromosome 13, Clin. Exp. Allergy 25 (Suppl) 2:61-63.
Louahed et al. (1995) IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones, J. Immunol. 154:5061-5070.
Miyazawa et al. (1992) Recombinant human interleukin-9 induces protein tyrosine phosphorylation and synergizes with steel factor to stimulate proliferation of the human factor-dependent cell line, M07e, Blood 80:1685-1692.
Nicolaides et al. (1997) Interleukin 9: a candidate gene for asthma, Proc. Natl. Acad. Sci. USA 94:13175-13180.
Petit-Frere et al. (1993) Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes, Immunology 79:146-151.
Postma et al. (1995) Genetic susceptibility to asthma- bronchial hyperresponsiveness coinherited with a major gene for atopy, N. Engl. J. Med. 333:894-900.
Rao et al. (1997) Practical approaches to remote asymmetric induction in steroidal side-chains utilizing oxazaborolidine reagents, J. Org. Chem. 62:4541-4545.
Renauld et al. (1990) Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene, J. Immunol. 144:4235-4241.
Renauld et al. (1992) Expression cloning of murine and human interleukin 9 receptor cDNAs, Proc. Natl. Acad. Sci. USA. 89:5690-5694.
Sears et al. (1991) Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children, N. Engl. J. Med. 325:1067-1071.
Yin et al. (1994) JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes, J. Biol. Chem. 269:26614-26617.
Jones Steve
Kinney William A.
Levitt Roy C.
Nicolaides Nicholas C.
Badio Barbara P.
Genaera Corporation
Morgan & Lewis & Bockius, LLP
LandOfFree
Asthma associated factors as targets for treating atopic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Asthma associated factors as targets for treating atopic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Asthma associated factors as targets for treating atopic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543090